DoD Gulf War Illness Treatment Evaluation Award | Apply Online

Opportunity Summary:

The DoD Gulf War Illness Treatment Evaluation Award (TEA) is a FY2016 funding opportunity under the Gulf War Illness Research Program that supports early-stage clinical testing of treatments aimed at improving the health and day-to-day functioning of Gulf War Veterans with Gulf War Illness (GWI). Although offered for the first time in FY16, it builds directly on the earlier FY08 to FY15 Innovative Therapeutic Evaluation Award mechanism. The core purpose is to generate credible early clinical evidence (proof-of-principle) that a proposed intervention can meaningfully improve GWI-related health outcomes, and to position promising approaches for larger, later-phase efficacy trials and eventual delivery to Veterans.

The program is focused on interventions that can improve overall functional status and/or key symptom clusters commonly seen in GWI, such as cognitive problems, musculoskeletal pain, gastrointestinal issues, fatigue, respiratory symptoms, skin abnormalities, and sleep difficulties. Applicants are expected to design Phase 0, Phase I, or Phase I/II pilot and early-phase clinical trials, with endpoints that clearly measure clinically relevant change in these outcomes, including how symptoms may interact rather than occur in isolation. The intent is not just to collect exploratory observations, but to produce data that is strong enough to justify the next step in clinical development.

A defining feature of the opportunity is that applicants must choose one of two tracks based on the maturity of the supporting evidence for the intervention. The Data-Based Treatment Track is for approaches backed by substantial preliminary evidence tied directly to GWI, such as results from GWI-relevant models, biological alterations identified in Veterans with GWI, or prior pilot trials in GWI that warrant replication or expansion. This track requires preliminary data, and it can include pharmacologic treatments as well as other physiologic interventions, including conventional, complementary, alternative, or combined approaches. The Symptom-Based Treatment Track is designed for more novel ideas that may have shown value in related conditions (for example, treatments studied in fibromyalgia or chronic fatigue syndrome) but have not yet been tested in Gulf War Veterans. For this innovation-focused track, preliminary data in GWI is not required, but the application must provide a rigorous and well-argued scientific rationale grounded in critical analysis of the literature and logical reasoning, preferably supported by peer-reviewed medical sources.

Operational readiness and clinical-trial quality expectations are central to this award. Proposed trials are expected to begin within 6 months of the award date, and that timeline includes completion of regulatory steps such as Institutional Review Board review and any other required approvals. Applications are expected to include a strong statistical analysis plan appropriate to the trial phase, along with a power analysis and sample size justification that matches the study objectives and is backed by appropriate statistical expertise. Applicants also need to demonstrate that the investigational product or materials (drug, compound, device, placebo when applicable, or other intervention resources) will be available in sufficient quantity, typically documented through a manufacturer letter or similar assurance, and that product quality aligns with applicable FDA manufacturing standards such as Good Manufacturing Practices or Quality System Regulation requirements.

Because these are clinical studies, the program strongly emphasizes compliance infrastructure and participant access. Applicants are encouraged to show experience working with the FDA (including prior submissions and regulatory interactions), and they must demonstrate real access to an appropriate Gulf War Veteran population sufficient to support meaningful outcomes. Collaboration with investigators who already have access to Gulf War Veteran cohorts is encouraged, particularly partnerships within the Department of Veterans Affairs, including the VA War Related Illness and Injury Study Centers. Proposals are also expected to include practical staffing, such as study coordinators who can shepherd the protocol through IRB and other approvals, manage multi-site coordination when relevant, and support recruitment and retention.

The application package is expected to address the full clinical trial lifecycle, not just the intervention concept. This includes clearly defined endpoints, adherence to Good Clinical Practice guidelines, a clinical monitoring plan for GCP compliance, a data management plan with an appropriate database to protect data integrity, and a safety management plan describing how pharmacovigilance and adverse event oversight will be handled when applicable. Applicants must also commit to registering the study on ClinicalTrials.gov, reinforcing transparency and alignment with common clinical research standards. In addition, proposals should include a transition plan describing how the intervention will move forward after the award, including likely funding paths and resources needed to advance to the next clinical phase and, ultimately, implementation for Veterans if results are positive. Strong institutional commitment and support are also expected to be clearly documented.

Industry participation is explicitly welcomed. Applications involving biotechnology or pharmaceutical companies, either as the main applicant or as collaborators, are encouraged, with an expectation that industry partners may leverage internal resources to supplement the award and help advance development efficiently. At the same time, the announcement draws a firm boundary around what it will not fund: applications primarily focused on treating psychiatric conditions, including post-traumatic stress disorder, are slated for administrative withdrawal and are not eligible under this opportunity.

From an administrative standpoint, this is a DoD (DOD-AMRAA) discretionary research and development opportunity offered as a grant and/or cooperative agreement under CFDA 12.420. Eligibility is broadly unrestricted (open to many entity types, subject to any additional eligibility notes in the full announcement). The posted closing date for this FY16 opportunity was October 20, 2016, and the program anticipated making about four awards; the award ceiling was not specified in the summary information provided.

Browse more opportunities from the same agency: DOD-AMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: DoD Gulf War Illness Epidemiology Research Award

Previous opportunity: DoD Gulf War Illness Clinical Partnership Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 16 GWIRP TEA

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 16 GWIRP TEA) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 16 GWIRP TEA", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.